|
 The deal will focus on early-stage research and the hope is that by
working together the companies will be able to identify promising
drug candidates much faster than working alone.
There is no financial commitment for the research involved and each
firm will contribute equal resources at their own cost.
Diabetes is a growing focus for many global drugmakers, reflecting
the spread of the type 2 form of the disease, which is linked to
obesity. Diabetic nephropathy occurs in up to half of patients who
have diabetes for 20 years or more.
(Reporting by Ben Hirschler; Editing by David Holmes)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column] |
